Oncotarget

Research Papers:

Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1

Claire F. Aspinall _, Daniella Zheleva, Anthony Tighe and Stephen S. Taylor

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:36472-36488. https://doi.org/10.18632/oncotarget.5507

Metrics: PDF 858 views  |   HTML 3031 views  |   ?  


Abstract

Claire F. Aspinall1, Daniella Zheleva2, Anthony Tighe1, Stephen S. Taylor1

1Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom

2Cyclacel Ltd, Dundee DD1 5JJ, United Kingdom

Correspondence to:

Stephen S. Taylor, e-mail: stephen.taylor@manchester.ac.uk

Keywords: mitosis, Plk1

Received: August 31, 2014     Accepted: September 30, 2015     Published: October 13, 2015

ABSTRACT

The quest to develop novel antimitotic chemotherapy agents has led to the generation of several small molecule inhibitors targeting Plk1, a protein kinase required for multiple aspects of cell division. Previous studies have shown that upon exposure to Plk1 inhibitors, cells enter mitosis, delay briefly in prophase and then arrest in mitosis due to an inability to undergo centrosome separation. Here, we show that four different classes of Plk1 inhibitor block mitotic entry in several cancer cell lines and non-transformed RPE-1 cells. The proportion of cells that arrest in G2 is cell line and concentration dependent, and is subject to non-genetic heterogeneity. Following inhibitor washout, the G2 block is alleviated and cells enter mitosis but then fail to complete cell division indicating that most Plk1 inhibitors are not fully reversible. An exception is CYC140844; in contrast to five other inhibitors examined here, this novel Plk1 inhibitor is fully reversible. We discuss the implications for developing Plk1 inhibitors as chemotherapy agents and research tools.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5507